Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs

CORCEPT THERAPEUTICS INC

Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.
William Guyer, formerly SVP at Gilead Sciences, appointed CDO effective Aug 16, 2021.
Guyer brings ~30 years of experience; led global Medical Affairs at Gilead, involved in multiple drug launches.
Separation agreement provides Grauer one-year salary continuation, COBRA coverage, and quarterly housing allowance.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Andreas Grauer

senior medical advisor

CORT · CORCEPT THERAPEUTICS INC

Effective: 2021-08-10
Filed: August 13, 2021, 7:59 PM ET

On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andreas Grauer changed role as senior medical advisor at CORCEPT THERAPEUTICS INC.

Action: agreed to serve as senior medical advisor
Role: senior medical advisor

Exact text from the filing

On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer.

View on SEC.gov

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-21-244963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.